Last reviewed · How we verify
NRL001
At a glance
| Generic name | NRL001 |
|---|---|
| Also known as | Methoxamine Hydochloride |
| Sponsor | Norgine |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- The Safety and Dose Response to Single Anal Doses of NRL001 (PHASE1)
- Safety and Tolerability of the Twice Daily Intra-anal Application of NRL001 Cream for 14 Days (PHASE1)
- A Multi-centre, Phase II, Double-blind, Randomised, Placebo-controlled, Parallel Group, Dose-ranging Study in Patients With Faecal Incontinence; to Evaluate the Efficacy, Safety and Tolerability of Locally Applied NRL001 Over an 8 Week Treatment Period (PHASE2)
- Effect of 7 Days of Dosing With a 10 mg Rectal Suppository of NRL001in Patients With Faecal Incontinence (PHASE1)
- Safety and Tolerability of a Single Intra-anal Dose of NRL001 in Healthy Volunteers (PHASE1)
- Safety, Tolerability, Pharmacodynamic and Pharmacokinetics of 7.5, 10, 12.5 or 15 mg NRL001 in a 2 g Suppository for 14 Days (PHASE1)
- Safety, Tolerability, Pharmacodynamic and Pharmacokinetics of a Single Rectal Application of 10 mg NRL001 in Elderly Subjects (PHASE1)
- Study of Escalating Doses of NRL001 Given in Slow-release Rectal Suppositories of Different Weights (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NRL001 CI brief — competitive landscape report
- NRL001 updates RSS · CI watch RSS
- Norgine portfolio CI